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Abstract
Background: Calcimimetics, such as R-568, are thought to activate G protein-linked Ca
2+-sensing receptor (CaSR) by
allosterically increasing the affinity of the receptor for Ca
2+ allowing for efficient control of uremic hyperparathyroidism.
Several recent studies suggest they possess additional vascular actions. Although it has been postulated that calcimimetics
may have a direct effect on CaSR in the blood vessels, further studies are needed to elucidate their vascular CaSR-dependent
versus CaSR-independent effects.
Methodology/Principal Findings: Focusing on human umbilical vein endothelial cells (HUVECs), we studied the CaSR
expression and distribution by Immunofluorescence and Western Blot analysis. CaSR function was evaluated by measuring
the potential effect of calcimimetic R-568 and its enantiomer S-568 upon the modulation of intracellular Ca
2+ levels (using a
single cell approach and FURA-2AM), in the presence or absence of Calhex-231, a negative modulator of CaSR. To address
their potential vascular functions, we also evaluated R- and S-568-stimulated enzymatic release of Nitric Oxide (NO) by DAF-
2DA, by Nitric Oxide Synthase (NOS) radiometric assay (both in HUVECs and in Human Aortic Endothelial Cells) and by
measuring eNOS-ser1177 phosphorylation levels (Immunoblotting). We show that, although the CaSR protein was
expressed in HUVECs, it was mainly distributed in cytoplasm while the functional CaSR dimers, usually localized on the
plasma membrane, were absent. In addition, regardless of the presence or absence of Calhex-231, both R- and S-568
significantly increased intracellular Ca
2+ levels by mobilization of Ca
2+ from intracellular stores, which in turn augmented NO
release by a time- and Ca
2+-dependent increase in eNOS-ser1177 phosphorylation levels.
Conclusions/Significance: Taken together, these data indicate that in human endothelium there is no stereoselectivity in
the responses to calcimimetics and that CaSR is probably not involved in the action of R- and S-568. This suggests an
additional mechanism in support of the CaSR-independent role of calcimimetics as vasculotrope agents.
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Introduction
Calcimimetics represent a new therapeutic opportunity for
treating mineral metabolism disorders related to secondary
hyperparathyroidism in patients suffering from chronic kidney
disease and uremia [1].
In humans, the parathyroid gland cells can sense small
fluctuations in plasma calcium (Ca
2+) levels by virtue of a cell
surface calcium sensing receptor (CaSR), which is a low-affinity G
protein-coupled receptor consisting of 1078 amino acid residues
[2–4]. Although Ca
2+ itself can be considered the main activator of
CaSR, there is a list of known direct (type I agonists) and indirect
allosteric (type II agonists) regulators of CaSR functions. Thus, it
seems to be a promiscuous receptor that senses changes in multiple
physiologic parameters [5]. In the parathyroid glands the class of
calcimimetics binds in a stereospecific way [6,7] to CaSR, and
through allosteric activation renders it more sensitive to extracel-
lular Ca
2+ concentration ([Ca
2+]o), subsequently resulting in
reduction of parathyroid hormone (PTH) secretion and improve-
ment of calcium phosphate products [8].
In addition to the organs specifically involved in Ca
2+
homeostasis, CaSR is widely expressed in many other tissues
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30682including blood vessels [9]. Thus, although most studies on CaSR
signaling have been performed in parathyroid cells and human
embryonic kidney cells stably transfected with CaSR, evidence of a
functional CaSR in endothelial cells from animal model and
human blood vessels has been provided [10–12].
Recently GPRC6A, a novel G protein-coupled receptor
(designated family C, group 6, subtype A) that is sensitive to
Ca
2+ and closely related to CaSR [13] has been identified in
endothelium of rat mesenteric and coronary arteries [14] and,
notably, can be activated by NPS R-568 [15], a known positive
allosteric modulator of the CaSR.
Thus, although the vascular effect of calcimimetics may depend
on calcimimetic-induced suppression of parathyroid hypertensive
factors [16], direct effects on blood vessels by calcimimetics, via
CaSR and/or other mechanisms, cannot be excluded [17].
According to this hypothesis, recent studies have demonstrated
in vivo hypotensive effects by calcimimetic agents (type II agonists)
in both normotensive [18] and spontaneously hypertensive rats
[19]. In addition, Koleganova et al. [20] have now further
extended the above observations concerning R-568 on vascular
remodeling both in control and in uremic rats.
More recently, it has been demonstrated in vitro that human
aortic endothelial cells express a functional CaSR that responds to
the endogenous polyamine spermine (CaSR type I agonist) by an
increase in intracellular calcium levels([Ca
2+]i), leading to the
production of Nitric Oxide (NO) [11]. NO is a gaseous molecule
which has pleiotropic effects in the regulation of vascular tone [21]
and is able to maintain vascular homeostasis [22].
Of note, Nakagawa and coll. [23] have shown acute
cardiovascular effects in rats by the type II agonist calcimimetic
R-568, and its enantiomer S-568. Since this molecule has no or
very little activity on the CaSR, the hypotensive effect of R-568
was most likely not mediated via CaSR.
Furthermore, ex vivo studies in isolated arteries have demon-
strated some CaSR-independent relaxant effects by calcimimetics,
predominantly acting by inhibiting Ca
2+ influx through L-type
Ca
2+ channels into vascular smooth muscle [24]. Thus, although
multiple lines of evidence suggest that calcimimetics might
participate in the modulation of a number of vascular functions,
we still need to elucidate the CaSR-dependent versus CaSR-
independent effects of calcimimetics.
Since it has previously been demonstrated that human aortic
endothelial cells express a functional CaSR [11], the principal
aims of the present study were first to assess the presence and
localization of CaSR in human vein endothelium and then to
evaluate its potential function by measuring the effect of
calcimimetics R-568 and its enantiomer S-568 on the modulation
of intracellular Ca
2+ levels. Secondly, in view of the key role of
intracellular calcium levels in the modulation of endothelial Nitric
Oxide Synthase (eNOS) enzymatic activity [25] and the
fundamental actions of released NO in the modulation of
vascular functions, we evaluated the effects of calcimimetics R-
568 and S-568 on the mechanisms of eNOS activation and NO
production in both human venous and aortic endothelial cells
(HAECs).
Results
Immunofluorescence and Western blot analysis for CaSR
expression in HUVECs
To determine whether CaSR protein was expressed in
HUVECs, immunofluorescence confocal microscopy analysis
was performed using a monoclonal antibody against human
CaSR. Excited ALEXA-488 emits green fluorescence. Nuclei
stained with TO-PRO-3 Iodide display blue fluorescence. As
shown in Fig. 1A, diffuse strong green fluorescence was observed
in permeabilized HUVECs, demonstrating a mainly intracellular
localization of CaSR protein. This evidence was confirmed by the
low number of green fluorescent non-permeabilized HUVECs
(Fig. 1C), thus demonstrating the major localization of the CaSR
in the cytosol in this cell type despite the alleged plasma membrane
localization of the mature functional protein. Again shown in
Figs 1B and 1D, the absence of primary antibody completely
abolished CaSR immunofluorescence, respectively in permealized
and non-permeabilized HUVECs.
In order to better identify CaSR expression and cellular
distribution, Western Blots were also performed. Fig. 1E shows
the immunodetection of CaSR under reducing conditions. As
compared to positive controls (Human Aortic Vascular Smooth
Muscle Cells [HAoVSMCs] and Human Aortic Endothelial Cells
[HAECs]) we identified not only a band of the size expected for
the full-length CaSR monomer (100–130 kDa), but the appear-
ance of strongly immunoreactive polypeptides of approximately
55–70 kDa and the presence of small polypeptides (30–40 kDa)
which have been attributed to degradation of CaSR. Moreover, in
agreement with our own observations on HUVECs, it has been
reported that immunodetection of the CaSR isolated from
HAoVSMCs shows a CaSR-specific immunoreactive band of
approximately 200 kDa [26]. Thus, the observed pattern of bands
(200, 100–130, 55–70 and 30–40 kDa) is consistent with results
from others who have detected CaSR at several different
molecular weights depending upon the extent of glycosylation of
the proteins and whether the CaSR is seen as a monomer or
multimer.
Figure 1. CaSR protein expression in HUVECs by Immunofluorescence Confocal Microscopy and Western Blot. Immunofluorescent
localization of CaSR in HUVECs with specific antibody and negative control after fixation and permeabilization protocol (A and B), or after fixation but
not membrane permeabilization (C and D). Representative Western Blot of CaSR protein levels in HAoVSMC, HAEC and HUVEC total lysate, and in
HUVEC membrane and cytoplasm extracts (E).
doi:10.1371/journal.pone.0030682.g001
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ascertain whether CaSR is located in the plasma membrane, in
which case it would exert its currently known physiological
function. Although we were consistently able to detect the widely
described immunoreactive 55–70 kDa polypeptide in both
subcellular compartments analyzed, it became evident from the
Western Blot analysis that the subfraction containing plasma
membranes was poorly enriched in an immunoreactive band of
distinctively higher molecular mass (100–130 kDa, totally absent
in cytoplasm fraction), suggesting the absence of the CaSR mature
monomers, physiologically relevant in HUVECs. Since it has been
reported [27] that the mature functional CaSR that resides on the
cell surface is mainly in the form of a dimer corresponding to a
molecular mass of approximately 250–280 kDa (or higher,
depending on the extent and type of glycosylation), we also
evaluated crude HUVEC protein extract. This molecular mass is
not consistent with the band that we find (data not shown),
suggesting the absence of the mature, physiologically relevant
CaSR in HUVECs.
Effects of R-568 and S-568 on HUVEC intracellular [Ca
2+]i
To determine whether the addition of R- and S-568 might
modulate [Ca
2+]i in our cellular model, FURA-2AM-loaded
HUVECs were stimulated using different concentrations (1–
100 mM) of R-568 or its enantiomer S-568. The evaluation of
[Ca
2+]i was also performed in the presence or absence of Calhex-
231 [28] at the highest calcimimetic concentration used (100 mM).
As shown in Fig.2 (A, B, C), R-568 caused a dose-dependent
increase in [Ca
2+]i. in almost all stimulated cells (responsive cells
were 92–100% of the cell population). At concentrations of 1 and
10 mM, R-568 induced a slow and delayed response, while at
100 mM, the compound produced a sustained rapid response.
The enantiomer, S-568, had the same qualitative and quantita-
tive effects as R-568 (Fig. 2, D, E, F). Notably, in the presence of
the inhibitor Calhex 231, 100 mM calcimimetics significantly
increased [Ca
2+]i, thus demonstrating that CaSR is not involved
in the action of R- and S-568 on the [Ca
2+]i rise (inset Panels C
and F).
Role of [Ca
2+]o in R-568 and S-568 induced changes
[Ca
2+]i in HUVECs
We tested whether in our cellular model the S- or R-568
triggered [Ca
2+]i. rise was driven only by extracellular Ca
2+ or also
by Ca
2+ release from internal stores. To this end, we performed
experiments in an extracellular Ca
2+-free condition (0mM Ca
2+ +
0.5mM EGTA) and/or in an empty store condition, using
thapsigargin (tg) to inhibit Ca
2+ re-uptake by intracellular stores
and consequently inducing store depletion [29]. In extracellular
Ca
2+-free conditions, R-568 and S-568 produced the same
qualitative and quantitative effects as shown in complete medium
(2mM Ca
2+) (Fig. 3A and 3B). On the other hand, the presence of
1 mM tg inhibited the effect triggered by R-568 and/or S-568
(Fig. 3C and 3D), thus supporting the hypothesis that the R-568-
or S-568-induced [Ca
2+]i rise was due to ion release from
intracellular stores.
In addition, when experiments were performed with the two
conditions at the same time, the response to calcimimetic agents
disappeared (data not shown).
Effects of R-568 and S-568 on HUVEC NO production
The effects of R-568 and S-568 on NO release from cultured
HUVECs are shown in Fig. 4. In these experiments NO release
was measured in the total cell population by a semi-quantitative
and high-sensitive method, demonstrating that DAF-2DA-loaded
Figure 2. Effects of different doses of R-568 or S-568 on HUVECs [Ca
2+]i. Traces (mean value 6 SE) representing [Ca
2+]i variations in FURA-
2AM-loaded HUVECs stimulated with R-568 (A–C) or S-568 (D–F) at 1 mM (A and D), 10 mM (B and E) or 100 mM (C and F) concentrations.
Representative traces after stimulation with R-568 100 mM + Calhex 10 mM (inset C) or S-568 100 mM + Calhex 10 mM (inset F).
doi:10.1371/journal.pone.0030682.g002
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doses of 1–100 mM) and S-568 (100 mM), in the presence of 2mM
[Ca
2+]o (Fig. 4A). The experiments were performed in the
presence or absence of Calhex-231, a negative modulator of
CaSR. In the presence of Calhex-231 (10 mM), R-568 stimulated
NO release at all concentrations used. Similar data were obtained
when S-568 was examined over the same concentration range,
showing that there is no stereoselectivity in the responses. Thus,
CaSR is unlikely to be involved in the action of R- and S-568.
In order to determine in our cellular model whether R-568 and
S-568 stimulated NO release by modulation of ser1177 phos-
phorylation levels of eNOS, we evaluated the effect of calcimi-
metics on eNOS-ser1177 phosphorylation (p-eNOS) levels in the
presence of 2mM [Ca
2+]o. p-eNOS levels were investigated by
Western Blot analysis using antibodies specific for the residue
ser1177, which is phosphorylated in activated eNOS.
As compared to controls, R-568 and S-568 significantly
stimulated eNOS-ser1177 phosphorylation in a dose-dependent
manner, as assessed by evaluation of total and p-eNOS (Fig. 4B
and 4C). Note that, parallel to calcimimetic stimulated NO
production, eNOS-ser1177 phosphorylation levels were enhanced
after R- and S-568 stimulation to a similar extent, regardless of
whether they had been treated with Calhex-231. Thus, CaSR is
not likely to be involved in this action by R- and S-568.
Effects of extra- and intra-cellular calcium levels in R-568-
and S-568-increased HUVEC NO release
Since a 100 mM concentration of either of R-568 or S-568
brought a sustained NO rise without any effect on cell morphology
and adhesion features, we used this concentration to evaluate the
role of calcium in calcimimetic-induced intracellular NO produc-
tion in HUVECs by a single cell approach [30]. As expected, in
the presence of 2mM [Ca
2+]o, both 100 mM R- and S-568
brought a rapid and sustained intracellular NO rise in almost all
cultured HUVECs (Fig. 5A, 5B). These effects appeared to be
Ca
2+-dependent, since R-568- or S-568-induced NO production
was completely abolished in Ca
2+-free conditions (Fig. 5C). In
addition, when a NO donor (sodium nitroprusside, SNP) was
added in these conditions, the gas was rapidly detected, thereby
indicating the integrity of the experimental system (Fig. 5C).
In order to determine the dependence of R-568- and S-568-
stimulated eNOS-ser1177 phosphorylation levels on modulation of
[Ca
2+]i, we also evaluated the effect of calcimimetics on p-eNOS
levels in Ca
2+-free conditions.
As compared to controls (time 0), R-568 and S-568 significantly
(p,0.003) stimulated eNOS-ser1177 phosphorylation, which
peaked at 0.5 to 1 minute of treatment, as assessed by evaluation
of total and Ser1177-phosphorylated forms of eNOS (Fig. 5D).
After 1 minute of calcimimetic incubation, their stimulatory effect
on eNOS-ser1177 phosphorylation was totally abolished by Ca
2+-
free conditions, thus demonstrating that the mechanism leading to
calcimimetic-induced NO release may potentially be mediated by
both R- and S-568-increased intracellular [Ca
2+]i levels and
eNOS-ser1177 phosphorylation. In fact, it is known that agonist-
stimulated intracellular calcium transients may form some of the
initial steps in eNOS activation, and may be required for further
activation of eNOS by other agonist-mediated pathways like
phosphorylation.
Effects of R-568 and S-568 on HUVEC and HAEC NOS
activity
In order to confirm the calcimimetic role on NO release in
HUVECs and to evaluate for the first time the potential effects of
R- and S-568 on NO enzymatic release in HAECs we evaluated
NOS activity by a highly sensitive method as the 3H-Arginine into
3H-Citrulline conversion assay.
Figure 3. Effects of R-568 or S-568 on HUVECs [Ca
2+]i without extra or intracellular Ca
2+. Representative Ca
2+-variations in FURA-2AM-
loaded HUVECs stimulated with 100 mM R-568 or 100 mM S-568 in Ca
2+ free medium (A and B) or after depletion of intracellular Ca
2+ stores by
thapsigargin (tg) (C and D).
doi:10.1371/journal.pone.0030682.g003
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stimulated by R-568 and S-568 at all doses employed (p,0.05).
Preincubation with L-NAME (1 mM), a known NOS inhibitor,
totally abolished the R- and S-568 increased NOS activity in both
cell strains (data not shown). On the contrary, Calhex-231 (10 mM)
did not significantly inhibit R- and S-568 stimulation of NO
release at any concentration, confirming that there is no
stereoselectivity in the responses.
Discussion
The present study shows for the first time that, although CaSR
protein was expressed in HUVECs, it was mainly distributed in
cytoplasm while the functional CaSR dimers, usually localized on
the plasma membrane, were absent. Nonetheless, both calcimi-
metics R- and S-568 significantly increased intracellular Ca
2+
levels by mobilization of Ca
2+ from intracellular stores, which in
turn augmented NO release by a time- and Ca
2+-dependent
increase in eNOS-ser1177 phosphorylation levels. One should
note that, in the presence of Calhex-231 (a negative modulator of
CaSR), R-568 increased both [Ca
2+]i levels and NO release at all
concentrations used. Similar data were obtained when S-568 was
examined over the same concentration range, showing that there
is no stereoselectivity in the responses. Thus, CaSR is unlikely to
be involved in the action of R- and S-568.
Our interest in this study stemmed from learning that, in addition
to the known role of calcimimetics in regulating levels of PTH [1], a
novel role has been proposed for calcimimetics as vasculotropes
[31].Thisissupportedbythe demonstration that CaSR isexpressed
in the arterial wall [26], both in vascular arterial endothelial and in
smooth muscle cells [10,11,32], as well as by animal model studies
showing a direct significant beneficial effect by R-568 on
hypertension and on calcification and vascular remodelling in both
uremic and control rats [17]. No studies in humans have been
designed so far to evaluate any direct cardiovascular effects by
calcimimetics. However, a recent prospective study did show that
after a 6-month follow-up, the mean blood pressure in 14 renal
transplant recipients receiving cinacalcet for persistent hyperpara-
thyroidism diminished significantly (from 94.1 to 88.0 mmHg,
p,0.019) with no changes in antihypertensive treatment [33].
Moreover, data obtained in over 600 End-Stage Renal Disease
(ESRD) patients from phase 3 studies with the calcimimetic agent
cinacalcet indicate lower systolic and diastolic blood pressure (BP)
values after one year of treatment (144.462.4 and 78.661.5 versus
138.662.4 and 76.961.5 mmHg, respectively) (personal commu-
nication, U. Fraass, Amgen, March 2005). Clearly, since it is not yet
clear whether the in vivo vascular function of R-568 is related to its
effect on systemic calcium homeostasis or exerts a direct effect on
the vasculature, additional focused studies are needed to establish
the impact of calcimimetic agents on potential NO release and BP
regulation in ESRD, a pathological state characterized by reduced
vascular NO bioavailability [34].
On the other hand, experimental studies ex vivo as well as on
cultured cells support the hypothesis that both R- and S-568 may
play a direct role in vascular functions. For example, in in vitro
and ex vivo experiments, activation of CaSR seems to have a
potential role in the control of vasodilation regulating the
myogenic tone in rat subcutaneous arteries, while treatment with
the type II CaSR agonist cinacalcet results in a concentration-
dependent vasodilatation of isolated precontracted aortae [12].
Although these data suggest a direct effect by calcimimetics on
the vasculature and in particular on the modulation of NO
bioavailability, which is known to play a key role in the regulation
of endothelial-mediated vasodilation and vascular homeostasis
Figure 4. Effects of R-568 or S-568 +/- Calhex (10 mM) on
HUVECs NO production. NO levels (mean value 6 SE) in DAF-2DA-
loaded HUVEC populations treated with R-568 or S-568 (1–100 mM) +/-
Calhex 10 mM (A). eNOS-ser1177 phosphorylation in HUVECs stimulated
with R-568 (B) or S-568 (C) (0.1–100 mM) +/- Calhex (10 mM).
Representative immunoblot of eNOS-ser1177 phosphorylation (Upper
Panel, B and C). Representative data from three experiments (means 6
SD, Lower Panel, B and C). Phospho-eNOS (p-eNOS) expression was
normalized vs total eNOS expression.
doi:10.1371/journal.pone.0030682.g004
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cellular mechanism(s) potentially involved in the in vivo vascular
effects observed with R-568.
Based on recent in vitro evidence from cultured human aortic
endothelial cells showing that these cells express CaSR and that
the agonist spermine induces an increase in [Ca
2+]i leading to the
Figure 5. Effects of 100 mM R-568 and S-568 with and without extra and intracellular Ca
2+ on NO production. Intracellular NO levels
(mean value 6 SE) in DAF-2DA-loaded HUVECs (A–C). Time effect of R-568 or S-568 100 mM on eNOS-ser1177 phosphorylation (D). Representative
immunoblot of eNOS-ser1177 phosphorylation (Upper Panel). Representative data from three experiments (means 6 SD, Lower Panel, p,0.003 vs
09). Phospho-eNOS (p-eNOS) was normalized vs eNOS total.
doi:10.1371/journal.pone.0030682.g005
Table 1. Effects of R-568 and S-568 on HUVEC and HAEC NOS activity.
HUVECs (pmoles NO/min/mg total protein) HAECs (pmoles NO/min/mg total protein)
Control 0.1560.01 0.1260.01
R-568 (1 mM) 0.2660.03* 0.2460.02*
R-568 (10 mM) 0.2860.02* 0.2660.03*
R-568 (100 mM) 0.3060.03* 0.2360.01*
S-568 (1 mM) 0.2460.01* 0.2060.02*
S-568 (10 mM) 0.2660.02* 0.2260.03*
S-568 (100 mM) 0.2760.03* 0.2660.003*
*p,0.05 (R- and S-568 vs Control).
doi:10.1371/journal.pone.0030682.t001
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and its enantiomer S-568 are able to increase NO release both in
HAECs and in HUVECs through eNOS activation. Although
these calcimimetic concentrations (1–100 mM) are 10–100 times
higher than those needed to treat uremic hyperparathyroidism in
vivo [6,7], they are close to the levels that the drugs reach in
animal models after oral administration. In support of this,
Nakagawa et al. [23] demonstrated that in vivo both R-568 and S-
568 increased mesenteric and renal blood flow when organ artery
blood concentrations of both compounds reached 70 mM, leading
us to hypothesize that the in vivo vascular effects of these
compounds may be mediated by increased endothelial NO
release. Notably, the effects of S-568 in these experiments were
almost identical with those of R-568, indicating a CaSR-
independent mode of action.
In agreement with these findings, our in vitro data show that in
HUVECs both R- and S-568 exert the same effects and in
particular their ability to increase [Ca
2+]i (Figs 2 and 3), NO levels
(Figs 4 and 5) and NOS activity in HUVECs and HAECs (Table 1)
is unaffected by Calhex-231 (a negative modulator of CaSR),
supporting the idea of a potential vascular CaSR-independent
rather than CaSR-dependent effect.
Regarding the mechanism(s) potentially involved in explaining
the vasculotropic effect of such calcimimetics, our data show that
the proven ability of calcimimetics is unaffected in Ca
2+-free
medium conditions while it is abolished after depletion of the
intracellular Ca
2+ pool by thapsigargin, indicating that the effect is
independent of [Ca
2+]o and possibly mediated by no stereoselec-
tive R-568 and S-568 interaction with G protein-coupled
receptors. Note that activation of this kind of receptor is known
to trigger complex intracellular signals through G-protein and
phospholipase-C, which in turn stimulate inositol-triphosphate
production and thereby increase intracellular Ca
2+ release [5,11].
In support of this hypothesis, recently GPRC6A, a novel G
protein-coupled receptor (designated family C, group 6, subtype A)
that is sensitive to Ca
2+ and closely related to CaSR [13], has been
identified in endothelium of rat mesenteric and coronary arteries
[14] and, notably, can be activated by NPS R-568 [15], a known
positive allosteric modulator of CaSR.
Thus, we may conjecture that in HUVECs R-568 or S-568
might allosterically modulate a member of the GPCR family C or
specifically GPRC6A activity and in turn activate various
intracellular pathways leading to increased eNOS activity and
then NO production.
Interestingly, in our cellular model the [Ca
2+]i increase drives
both R- and S-568 NO production. Thus, when [Ca
2+]i increase is
almost completely prevented, the R- and S-568 effects on NO
release are totally abolished (Fig. 5). The mechanism may be
clarified by reflecting that in endothelium NO release is due to
eNOS activation which results from a complex combination of
protein-protein interaction and signal transduction cascades
involving calcium mobilization and/or phosphorylation events.
In particular, several agonists that raise intracellular calcium
concentrations, such us bradykinin, promote Ca
2+/calmodulin
binding to eNOS and caveolin dissociation from the enzyme,
resulting in an activated eNOS-complex. This concept has been
greatly refined to include a complex array of protein-protein
interactions that can lead to increased eNOS phosphorylation due
to interaction with Hsp90. In fact, the interaction between eNOS
and Hsp90 can induce formation of ternary complex which
includes the kinase Akt. This might significantly contribute to
increasing p-eNOS levels and then eNOS activity [35].
Moreover, multiple protein kinases can modify eNOS activity
through effects on serine phosphorylation at position 1177, which,
in turn, influence NO release [36].
In point of fact, in our experimental model both R- and S-568
rapidly and significantly increased eNOS-ser1177 phosphorylation
levels (p,0.003) and these calcimimetic effects on eNOS
phosphorylation disappeared in Ca
2+-free conditions, indicating
that both R- and S-568 stimulated NO release needs [Ca
2+]i in
order to rise (Fig. 5).
From these data it is conceivable that the potential non
stereospecific activation of a G protein-coupled receptor by R-or
S-568 elicits additional intracellular signals, potentially through
interaction with Gaq/11 subunit heterotrimeric G-proteins,
resulting in potential activation of a PI3-Kinase/Akt cascade
leading to increased eNOS phosphorylation levels [5].
Moreover, since the activation of eNOS in endothelial cells
involves a complex set of molecular events all acting in concert to
increase eNOS activity, further studies will be needed to evaluate
the potential role of R-568 or S-568 in the modulation of eNOS
activity via intracellular enzyme compartmentalization and/or
protein-protein interactions [36].
The present study provides further insight into the potential
CaSR-independent novel role of calcimimetics in vascular biology,
by showing that these compounds increase NO release in cultured
HUVECs. It should be noted, however, that, as with the CaSR-
independent vasodilatory action of both R-568 and S-568
demonstrated by Nakagawa et al. [23], so the in vitro effect was
observed with high compound concentrations, exceeding those
required for modulation of PTH secretion. Thus, the implications
of such vasculotropic effects for clinical purposes remain to be
established.
Nevertheless, that [Ca
2+]o-independent endothelial NO pro-
duction was increased by calcimimetics, as observed in our study,
may support the previous suggestion by Al-Aly [31], namely that
CaSR and/or other mechanisms may be implicated in several
cellular processes and that translational applications of calcimi-
metics may not be exclusively calcium-centric. This provides a
new impetus for further investigations aiming to characterize
calcimimetics as vasculotropes, which would open new perspec-
tives as to the CaSR-independent role of these compounds in
regulating the endothelial function in uremia and, more generally,
as to their role as vasculotrope agents.
Materials and Methods
Chemicals
Powered R-568-HCl and S-568-HCl were provided by Amgen
(Amgen, Inc., Thousand Oaks, CA, USA), resuspended in water at
2 mM concentration and stored at 220uC. Calhex-231 (Santa
Cruz, sc-207394) from Santa Cruz was resuspended in Ethanol at
10 mM concentration and stored at 220uC.
Ethics Statement
Umbilical cords were obtained from randomly selected healthy
mothers delivering at the Chieti and Pescara University Hospital.
All procedures were in agreement with the ethical standards of the
Institutional Committee on Human Experimentation (‘‘University
G. d’Annunzio Ethics Committee review board’’, Reference
Number: 1879/09COET) and with the Declaration of Helsinki
Principles. After approval of the protocol by the Institutional
Review Board, signed informed consent form was obtained from
each participating subject.
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Primary HUVECs were obtained and cultured as previously
described [37]. Briefly, after perfusion of umbilical cords with
0.1% collagenase at 37uC, HUVECs were grown on 0.2% gelatin-
coated tissue culture plates in 50:50 Dulbecco’s Modified Eagle’s
Medium-Low Glucose (DMEM) (PAA E15-806) and M199 (PAA
E15-834), supplemented with 20% FBS (PAA A15-101), 10 mg/ml
heparin, and 50 mg/ml ECGF (Sigma, Saint Louis, USA), 100 U/
ml penicillin-100 mg/ml streptomycin (PAA P11-010), 2 mM L-
Glutamine (PAA M11-004). In all experiments, cells were used
between the third and sixth passages in vitro and starved for
2 hours in EBM (Endothelial Basal Medium, without Fenol Red;
Lonza Clonetics CC-3129) supplemented with 1% platelet-
deprived horse serum and 100 mM L-arginine. HAoVSMCs and
HAECs (ATCC, USA) were employed as positive controls.
HAECs were also employed to evaluate NOS activity by
measuring the conversion of L-[
3H]-arginine into L-[
3H]-
citrulline.
Immunofluorescence
For Immunofluorescence Confocal Microscopy experiments,
HUVECs were plated onto glass gelatin-coated coverslips in 6-well
plates and grown at sub-confluence. Briefly, cells were fixed for
10 min at room temperature with a 3% paraformaldehyde
solution in 1X-Dulbecco’s phosphate buffered saline (PBS) 2%
sucrose (fixation solution pH 7.6). Then, cell membranes were
permeabilized (0.5% Triton X-100 20mM HEPES, 300mM
sucrose, 50mM NaCl, 3mM MgCl2, pH 7.6) for 5 min at room
temperature. Some not permeabilized samples were left in PBS for
5 min at room temperature. For CaSR/nucleus immune-labeling,
cells were blocked with 10% Bovine Serum Albumine (BSA) in
PBS for 30 min at room temperature, followed by 60 min
incubation at 37uC in a 1:100 dilution in 1% BSA in PBS of
anti human CaSR Mouse monoclonal antibody (MA1-934 ABR
Affinity BioReagents, CO, USA) raised against a synthetic peptide
corresponding to residues 214–235 of hCaR protein, at a final
concentration of 10 mg/ml. Finally, Alexa-488 (Molecular Probes
A11001) goat anti-mouse secondary antibody (1:1000) in 1%
BSA/PBS was incubated for 1 h at room temperature. For nuclear
staining, TO-PRO-3 Iodide (Molecular Probes T3605) in a 1:100
final dilution was added during the last 15 min of incubation.
Negative controls were processed as for CaSR staining, but
incubated only with Alexa-488 goat anti-mouse secondary
antibody. All the slides were mounted with Slowfade (Molecular
Probes), and observed with a ZEISS 510META Confocal
Microscope. Images were acquired using LSM 510 META
confocal microscopy software (rel. 3.0, ZEISS).
Western Blot Analysis
Total protein content, membrane and cytoplasm protein
fractions were isolated from untreated HUVECs and quantified
using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
IL, USA). 30 mg of HUVECs, of HAoVSMCs and HAECs
(positive controls) total protein lysates, and 15 mg of membrane
and cytoplasm extracts were heated at 100uC for 10 min in an
SDS sample buffer with 2-Mercaptoethanol (reducing conditions),
electrophoretically separated by 4–10% SDS-PAGE under
reducing conditions and electroblotted on nitrocellulose mem-
brane. The membranes were blocked in 5% milk solution in TBS-
Tween 20 0.1% (TBST) for 1 hour at room temperature and
probed with a 1:2000 dilution of anti-human CaSR mouse
monoclonal antibody (MA1-934 ABR) and with a 1:10000 dilution
of anti-human b-Actin mouse monoclonal antibody (Sigma
A5441) in 5% milk solution in TBS-Tween 20 0.1% at 4uC
overnight. After washing, the membranes were further incubated
with a 1:10000 dilution of Goat Anti-Mouse IgG specific
Peroxidase conjugated (Calbiochem, Merck, 401253) in 5% milk
solution in TBS-Tween 20 0.1% for 90 min at room temperature.
Immunoreactive bands were detected using the ECL system
(Amersham, GE Healthcare).
[Ca
2+]I measurement
For [Ca
2+]i measurements HUVECs (6000 cells/well) were
plated on black 96-well plates with a clear bottom in complete
medium. After 1 day the cultures were serum-starved for 2 hours
in EBM (phenol red-free endothelial basal medium) supplemented
with 1% platelet-deprived horse serum and 100 mM L-arginine. In
the last 45 min of serum-starvation 5 mM FURA-2AM was added
to the cells, then rinsed with Standard Medium (SM; 125mM
NaCl, 5mM KCl, 1mM MgSO4, 1mM KH2PO4, 5.5mM
Glucose, 2mM CaCl2, 20mM HEPES, pH 7.4) and bathed in
Ca
2+-containing SM. FURA-2AM-loaded cells were sequentially
excited at 340 and 380nm by a high-speed wavelength switcher
(PolychromeII, Till Photonics, Germany) equipped with 75W-
Xenon lamp (Ushio Inc., Japan) and stimulated with R-568 or S-
568 (1–10–100 mM). The effect of Calhex was tested on R-568 or
S-568 100 mM. To study the role of extra- and intra-cellular
Ca
2+,the cells were stimulated with R-568 or S-568 100 mM
respectively in Ca
2+-free SM and after depletion of intracellular
Ca
2+ stores by thapsigargin. The fluorescence images were
acquired every 2 sec by a C6790 cooled CCD camera (Hama-
matsu Photonics, Hamamatsu, Japan). The image ratio calcula-
tions were carried out on a pair of corresponding 340 and 380
image files. The graphs show the temporal plots calculated from
the image ratios (340/380). For each experimental condition, 10
different wells were observed to analyze at least 35–50 cells).
Measurement of intracellular NO levels
The total NO production was measured in HUVEC popula-
tions using a modified version of the method by Wang and Joseph
[38]. NO production was studied by using DAF-2DA (Calbio-
chem, Merck 251505) in the same culture conditions as used for
evaluating [Ca
2+]i variation. In the last 30 minutes of serum-
starvation 10 mM DAF-2DA was added to the cells, which were
finally rinsed in Standard Medium (SM; 125mM NaCl, 5mM
KCl, 1mM MgSO4, 1mM KH2PO4, 5.5mM Glucose, 2mM
CaCl2, 20mM HEPES, pH 7.4). DAF-2DA-loaded cells were
stimulated with R-568 or S-568 (1–10–100 mM) with or without
Calhex 231 (10 mM) in Ca
2+-containing SM or Ca
2+-free SM plus
thapsigargin. The NO donor Sodium Nitroprusside (SNP) was
used as a internal control. The fluorescence, read by a microplate-
reader (SPECTRAmax GEMINI XS, Molecular Devices, Toron-
to, Canada) at 490nm excitation/510nm emission, was acquired
from each sample (n=8) and expressed as a mean 6 SE of the f/fc
ratio (f=stimulated cells; fc=control cells).
NO production was studied in detail in the same culture
conditions using the method previously reported by Di Pietro
et al., 2006 [30]. Briefly, DAF-2DA-loaded cells bathed in either
Ca
2+-containing SM or in Ca
2+-free SM (CaCl2 was substituted by
2mM MgCl2 plus 0.5mM EGTA) plus 1 mM thapsigargin
administration, were excited at 490nm, and during fluorescence
recording were stimulated with R-568 or S-568 (1–10–100 mM).
The fluorescence images were sampled every 2 sec and traces were
calculated as f/f0 (f=fluorescence emission of a single DAF-2DA-
loaded cell; f0=fluorescence value of the same cell before the
addition of stimuli). At the end of each experiment, the NO donor
SNP (sodium nitroprusside) was used as an internal control. For
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eNOS-ser1177 phosphorylation analysis
HUVECs were grown at sub-confluence on Petri dishes 100mm
in complete medium and then serum-starved as described above.
To study the effects of different doses of R-568 or S-568 (0.1–1–
10–100 mM)+/- Calhex (10 mM) on HUVECs NO production,
the cells were bathed in Ca
2+-containing SM and stimulated for
1 minute. To study the effects of R-568 and S-568 (100 mM ) with
and without extra- and intracellular Ca
2+ conditions on NO
production, the cells were treated with R-568 or S-568 (100 mM)
time dependently (0, 0.5, 1, 2, 5 minutes) in Ca
2+-containing SM
and for 1 minute in Ca
2+-free SM. Total protein lisates were
recovered and quantified. eNOS-ser1177 phosphorylation levels
were determined by Western Blot after immunoprecipitation.
Briefly, 500 mg of lysate proteins were incubated overnight with
5 mg of eNOS mouse monoclonal antibody (Clone3, 610297 BD
Transduction labs) at 4uC, gently rocking. The next day 50 mlo f
50% slurry protein A/G beads (sc-2003 Santa Cruz) was added to
the mixture and incubated for 4 hours at 4uC, gently rocking.
After 3 washes with IP buffer (50nM HEPES pH 7.2, 1nM MgCl2,
1nM CaCl2, 2nM NaVO3, 10nM Na Pyrophosphate, 10nM NaF,
2nM EDTA pH 8, 10% glycerol, 1% NP40, 137nM NaCl,
200nM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin and 1 mg/
ml peptastatin) immunoprecipitates were resolved on an 8% SDS-
PAGE gel and transferred to nitrocellulose. Then, membranes
were blocked for 1 hour in 5% BSA in TBST and incubated with a
1:1500 dilution in 1% BSA of eNOS-Phospho ser1177 rabbit
polyclonal primary antibody (07–428, Upstate Biotechnology)
overnight at 4uC. After three washes with TBS-Tween 20 0.1%,
membranes were incubated with a 1:2000 dilution in 5% non-fat
milk in TBST of anti-rabbit IgG-HRP conjugate secondary
antibody (Santa Cruz sc-2004) for 90 minutes at RT. Immuno-
reactive bands for eNOS-Phospho ser1177 were visualized by
ECL Plus detection reagent (Amersham Pharmacia). To deter-
mine eNOS total content the membranes were stripped using a
Restore Blot Stripping Buffer (Thermo Scientific 21059) following
the manufacturer’s instructions and then re-probed with a 1:2000
dilution in 5% non-fat milkof the eNOS mouse monoclonal
antibody overnight at 4uC. After three washes with TBST,
membranes were incubated with anti-mouse IgG-HRP conjugate
secondary antibody (Calbiochem 401253, 1:10000 in 5% non-fat
milk) for 90 minutes at RT. Immune complexes were visualized by
ECL and quantified by scanning densitometry (Kodak digital
photocamera connected to a computer). The data were elaborated
by the Bio-Rad Image Processing and Analysis System. Phospho
eNOS was normalized vs eNOS total.
NOS activity
NOS activity was evaluated by measuring the conversion of L-
[
3H]-arginine into L-[
3H]-citrulline as described by [39]. Briefly,
HUVECs and HAECs were grown at confluence and were
stimulated with calcimimetics (1–100 mM) and/or Calhex-231
(10 mM). After that, cells were detached and then resuspended in
0.2 ml of reaction buffer (20 mmol/L Hepes-Na
+, 0.5 mmol/L
EDTA, 1 mmol/L dithiothreitol, pH 7.2) and sonicated on ice. In
each test tube the following reagents were added to 100 ml lysate at
the final concentrations: 2 mmol/L NADPH, 1.5 mmol/L CaCl2,
0.1 mmol/L BH4 (tetrahydrobiopterin) (Sigma-Aldrich, MO,
USA), 2.5 mCi L-[
3H]-arginine (=0.4 mM) (Amersham Pharmacia
Biotech, PA, USA). After 15 min incubation at 37uC, the reaction
was stopped by adding 2 ml Hepes-Na
+ pH 6 containing 2 mmol/
L EDTA; the entire reaction mixture was applied to 2 ml columns
of Dowex AGWX8-200 (Aldrich, Steinheim, Germany) (Na
+
form) and eluted with 4 ml of water. The radioactivity
corresponding to L-[
3H]-citrulline content in the eluate was
measured by a liquid scintillation analyzer (Packard Bio Science
Company, Meriden, CT, USA). In some experiments, L-NAME
(1mM/L; Sigma Chemicals) was added 40 min before adding L-
[
3H]arginine. NOS activity was expressed as pmoles citrulline/
min/mg protein.
Statistical analysis of data
Data are reported as means 6 SE or SD. Statistical
comparisons were made using Student’s t test for paired and
unpaired groups. An analysis of variance was used when multiple
comparisons were performed. A difference was considered
significant at p,0.05.
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